How to Get Semaglutide in the US

The short version: semaglutide isn’t a gray-market peptide

If you’ve read our pages on research peptides like BPC-157 or CJC-1295, set most of that mental model aside. Those compounds sit in a regulatory gray zone where a clinician can write a prescription but a pharmacy often has no clean legal basis to fill it. Semaglutide is the opposite. It is a fully FDA-approved drug, sold under several brand names:

• Ozempic — once-weekly injection, approved for type 2 diabetes.
• Wegovy — once-weekly injection, approved for chronic weight management and, in eligible patients, to reduce cardiovascular risk.
• Rybelsus — a daily oral tablet for type 2 diabetes.
• Wegovy pill — a once-daily oral tablet for weight management, FDA-approved in December 2025 and launched in early 2026. It is the first oral GLP-1 approved specifically for weight loss.

Because these are approved medicines, any licensed clinician — your own physician included — can write a normal prescription that any US pharmacy can dispense. There is no shortage-driven bottleneck to fill a brand script in 2026; the brands are stocked at retail pharmacies nationwide. That changes the entire question. With a research peptide, the hard part is legality and availability. With semaglutide, the hard part is cost and coverage, plus making sure you go through a real clinical evaluation rather than a sketchy shortcut.

Note: Semaglutide carries a boxed warning about a risk of thyroid C-cell tumors and is not appropriate for everyone. It requires a clinician’s assessment of your history, other medications, and goals. This page is about access routes, not about whether the drug is right for you — that’s a conversation for a qualified provider.

There are four practical routes. Here’s how they compare.

Route 1: Through your own doctor and a regular pharmacy

The most conventional route is also the one many people overlook because they assume their primary-care doctor won’t prescribe a GLP-1. In 2026, that assumption is increasingly outdated. Semaglutide for diabetes is squarely within primary-care practice, and prescribing it for obesity has become far more mainstream than it was even two years ago, especially now that the drugs are widely stocked and the manufacturer offers direct self-pay pricing.

How it works: you see your physician (in person or via your health system’s own telehealth), they evaluate whether you meet the clinical criteria — typically diabetes for Ozempic/Rybelsus, or a qualifying BMI with or without weight-related conditions for Wegovy — and write the prescription. You fill it at any pharmacy, or have it shipped through the manufacturer’s direct pharmacy.

Strengths: It uses an established relationship with someone who already knows your medical history, it bills your insurance directly if you’re covered, and it keeps your weight-management care connected to the rest of your health record. Limitations: Some primary-care doctors are still cautious about prescribing for weight loss alone, and if your plan doesn’t cover it, you’ll be navigating cost on your own — though the manufacturer’s self-pay program has narrowed that gap considerably.

This is the route to try first if you have insurance that might cover it, because your own clinician is best placed to handle prior authorization and appeals.

Route 2: Telehealth weight-loss platforms

Online platforms are how a large share of US patients now start semaglutide. You complete an intake questionnaire, sometimes upload labs or have them ordered, and a clinician licensed in your state reviews your case and — if appropriate — issues a prescription. The medication is then shipped to you or sent to a pharmacy.

The important 2026 context: many of these platforms originally grew on compounded semaglutide during the shortage, when copies sold for a fraction of the brand price. With the shortage resolved and enforcement active (more on that below), reputable platforms have shifted toward prescribing FDA-approved brand semaglutide, often routed through the manufacturer’s self-pay channel or filled on insurance. Some still advertise compounded GLP-1s; treat those claims with real caution and read our compounded-legality page before signing up.

Strengths: fast, convenient, and often the smoothest path for someone whose own doctor is hesitant. Platforms handle the prescription logistics and frequently bundle the consult into a flat monthly price. Limitations: quality varies enormously. A good platform does a genuine evaluation, checks for contraindications, and offers follow-up; a bad one is a rubber-stamp questionnaire. The difference matters for a drug with real side effects and a boxed warning.

Route 3: In-person obesity-medicine and weight-loss clinics

Dedicated obesity-medicine, bariatric, endocrinology, and weight-loss clinics offer a more hands-on version of the same pathway. You get a full evaluation, baseline labs, and a clinician who manages dose escalation, side effects, and monitoring over time, usually with in-person follow-up.

Strengths: the closest oversight, useful if you have other conditions, a complicated history, or you simply want a clinician watching the process closely. Many also coordinate nutrition and behavioral support. Limitations: typically the most expensive route once consults and labs are added, and it’s less convenient than telehealth. But for higher-risk patients, that added cost buys real medical supervision.

What about compounded semaglutide?

This is the part that’s changed most, and it’s the single biggest source of confusion in 2026. Here’s the honest picture.

During the 2022–2024 shortage, federal law allowed licensed pharmacies to compound their own semaglutide because the approved product was in short supply. Compounded versions sold for roughly a couple hundred dollars a month versus well over a thousand for brand Wegovy, and an entire telehealth industry was built on that price gap.

That window has largely closed. The FDA removed semaglutide from its drug shortage list in February 2025, with wind-down deadlines for traditional 503A pharmacies in April 2025 and for 503B outsourcing facilities in May 2025. Once a drug is no longer in shortage, compounders face strict limits on producing what the FDA calls “essentially a copy” of an approved product. Litigation in 2025 created some temporary uncertainty, but the FDA’s position has been upheld and enforcement is active.

Two things survive, narrowly:

• Patient-specific 503A compounding can still be lawful when a documented clinical need can’t be met by the commercial product — for example, a genuine allergy to an inactive ingredient. This is a real but limited exception, not a backdoor to cheap supply for everyone.
• In April 2026 the FDA went further and proposed formally excluding semaglutide and tirzepatide from the 503B bulk-drug list, which would foreclose bulk compounding even if a future shortage were declared. A public comment period on that proposal runs through late June 2026.

The takeaway: most large-scale “compounded semaglutide” being marketed online now operates outside the law, and the price advantage that justified the risk has shrunk as brand self-pay prices have fallen. If you’re currently on a compounded protocol, the right move is a clinical transition plan with a provider, not a panic — but new patients should be skeptical of anyone still leaning on the shortage-era pitch. We cover the full legal blow-by-blow on our compounded GLP-1 legal status page.

What it costs across routes (2026 snapshot)

Pricing is the whole ballgame for semaglutide, and it’s moved fast — so treat these as a current snapshot, not a quote, and verify before you commit.

• Retail cash price for brand Wegovy or Ozempic without any program runs well over a thousand dollars a month. Almost nobody should pay this; it’s the number to avoid.
• Manufacturer self-pay through the maker’s direct pharmacy has become the default cash route. List self-pay pricing has come down substantially from earlier in the program, with introductory pricing for new patients on the lowest doses and a separate, lower entry price for the oral pill. This is usually the cheapest legitimate brand option for the uninsured.
• Commercial insurance with a savings card can drop the monthly copay dramatically for eligible patients — in many cases to a token amount — but only if your plan actually covers the drug for your indication.
• Government plans (Medicare, most Medicaid, Tricare) generally do not cover GLP-1s for weight loss, though diabetes coverage is more common. Manufacturer savings programs typically exclude government beneficiaries.
• Telehealth bundles fold the consult and medication into a flat monthly fee; whether that beats going direct depends on the platform and your coverage.

A new wrinkle in 2026 is direct-to-consumer cash pricing tied to federal pricing deals, including discounted GLP-1 access through government-linked purchasing channels. These are evolving and worth checking, but the practical upshot is the same: between manufacturer self-pay and insurance, there is now a legal brand route for most budgets that didn’t exist at a reasonable price two years ago. Our semaglutide cost page goes deeper on the numbers and the insurance page covers coverage and appeals.

Which route makes sense for whom

No single route wins for everyone. A rough guide:

• You have insurance that might cover it → start with your own doctor (Route 1). They can run the prior authorization and appeal a denial, which is where most coverage battles are won.
• You want speed and convenience and your doctor is hesitant → a reputable telehealth platform (Route 2), prescribing brand rather than compounded.
• You have other health conditions or want close supervision → an in-person clinic (Route 3).
• You’re uninsured → compare manufacturer self-pay against telehealth bundles; the direct route is often cheapest for the brand.
• You’re tempted by cheap compounded semaglutide → understand that the legal basis has mostly evaporated and the savings have shrunk. Read up before you buy anything, and never treat a research-use-only vial as a patient route.

Whichever channel you choose, the non-negotiables are the same: a real clinical evaluation, a licensed prescriber, an FDA-approved product wherever possible, and ongoing follow-up. For how the prescription itself is written and what a good evaluation looks like, see our semaglutide prescription guide; for vetting any provider, see how to choose a clinic or telehealth provider.

Legal and regulatory details on this page are current as of the lastUpdated date and are changing quickly, particularly around compounding and pricing. Verify the current status before acting. This is educational information, not medical advice; talk to a qualified clinician about whether semaglutide is appropriate for you.